Literature DB >> 28376280

Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.

Elise M Weerts1, Gary S Wand1,2, Brion Maher1,3, Xiaoqiang Xu1, Mary Ann Stephens1, Xiaoju Yang2, Mary E McCaul1.   

Abstract

BACKGROUND: The current study examined independent and interactive effects of polymorphisms of the mu opioid receptor gene (OPRM1, A118G) and variable number tandem repeats of the dopamine transporter gene (DAT1, SLC6A3) on alcohol consumption and subjective responses to alcohol in 127 young, healthy, social drinkers.
METHODS: Participants completed an in-person assessment, which included self-reported alcohol drinking patterns and blood sampling for DNA, and in a second visit, a cumulative alcohol dosing procedure with subjective ratings across multiple time points and breath alcohol contents (0.03 to 0.1%). DNA was analyzed for OPRM1 AA versus AG/GG (*G) genotypes, DAT1 10-repeat allele (A10) versus 9 or lesser alleles (A9), and ancestral informative markers.
RESULTS: There were significant epistatic interactions between OPRM1 and DAT1 genotypes. Subjective High Assessment Scale scores after alcohol consumption were highest in *G and A9 carriers, and lowest in *G and A10 carriers. Negative subjective effects were also highest in *G and A9 carriers. Effects were similar in a sensitivity analysis limited to Caucasian subjects. There were independent and epistatic interactions on drinking. The OPRM1 *G allele was independently associated with fewer heavy drinking days. The A9 allele was associated with a greater number of drinking days, which was attenuated in carriers of the *G allele.
CONCLUSIONS: These findings highlight the biological importance of interactions between these 2 genes and interactions between brain opioid and dopamine systems.
Copyright © 2017 by the Research Society on Alcoholism.

Entities:  

Keywords:  A118G; Alcohol; Dopamine Transporter Gene; Intermediate Phenotype; Mu Opioid Receptor Gene; Polymorphism

Mesh:

Substances:

Year:  2017        PMID: 28376280      PMCID: PMC5483245          DOI: 10.1111/acer.13384

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  58 in total

1.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

Review 2.  The reward circuit: linking primate anatomy and human imaging.

Authors:  Suzanne N Haber; Brian Knutson
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 3.  Common single nucleotide variants underlying drug addiction: more than a decade of research.

Authors:  Kora-Mareen Bühler; Elena Giné; Victor Echeverry-Alzate; Javier Calleja-Conde; Fernando Rodriguez de Fonseca; Jose Antonio López-Moreno
Journal:  Addict Biol       Date:  2015-01-21       Impact factor: 4.280

4.  Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Authors:  Marta Peciña; Tiffany Love; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-10-13       Impact factor: 7.853

5.  The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression.

Authors:  S Fuke; S Suo; N Takahashi; H Koike; N Sasagawa; S Ishiura
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

6.  Self-rating of alcohol intoxication by young men with and without family histories of alcoholism.

Authors:  M A Schuckit
Journal:  J Stud Alcohol       Date:  1980-03

7.  A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

8.  Dopamine transporter (DAT1) VNTR polymorphism and alcoholism in two culturally different populations of south India.

Authors:  Lakkakula V K S Bhaskar; Kumarasamy Thangaraj; Samiksha Wasnik; Lalji Singh; Vadlamudi Raghavendra Rao
Journal:  Am J Addict       Date:  2012-05-16

9.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Arch Gen Psychiatry       Date:  2007-09

10.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more
  5 in total

Review 1.  A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity.

Authors:  Marc A Schuckit
Journal:  Alcohol Clin Exp Res       Date:  2018-04-05       Impact factor: 3.455

2.  The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption.

Authors:  M E Sloan; T D Klepp; J L Gowin; J E Swan; H Sun; B L Stangl; V A Ramchandani
Journal:  Neuropsychopharmacology       Date:  2018-02-02       Impact factor: 7.853

3.  Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.

Authors:  Raymond F Anton; Konstantin E Voronin; Sarah W Book; Patricia K Latham; Patrick K Randall; Willam Bailey Glen; Michaela Hoffman; Joseph P Schacht
Journal:  Alcohol Clin Exp Res       Date:  2020-09-19       Impact factor: 3.455

4.  The effects of oral and vaporized cannabis alone, and in combination with alcohol, on driving performance using the STISIM driving simulator: A two-part, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory protocol.

Authors:  C Austin Zamarripa; Matthew D Novak; Elise M Weerts; Ryan Vandrey; Tory R Spindle
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

5.  Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.

Authors:  Joseph P Schacht; Michaela Hoffman; Brian H Chen; Raymond F Anton
Journal:  Pharmacogenomics J       Date:  2021-08-11       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.